drugset / Trial / NCT00715364
REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
To assess the safety and tolerability of NTx™-265 when given to acute ischemic stroke patients. To assess the neurological outcome in acute ischemic stroke patients treated with NTx™-265, when compared with patients given a placebo control.
Timeline
- Start
- 2009-08
- Primary completion
- 2010-06
- Completion
- 2010-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epoetin Alfa (EPO) | Unknown | 30000 iu | Intravenous |
| Subject | Human Chorionic Gonadotropin (hCG) | Unknown | 385 ug | Subcutaneous |